PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34923902-8	2021	When TAT was coupled to the eNOS-RRKRK sequence, protection against LPS-induced permeability was still demonstrated, however cytokine production was not reduced.	Triethylenemelamine	5-8	nitric oxide synthase 3	Homo sapiens	28-32
15211655-4	2004	The direct sequencing of SRY showed a new nonsense mutation in a codon of SRY gene flanking the 3" end of the HMG domain: a thymine is replaced by a guanine at position +387 in codon 129, resulting in the replacement of the amino acid tyrosine (TAT) by a stop codon (TAG).	Triethylenemelamine	245-248	sex determining region Y	Homo sapiens	25-28
15211655-4	2004	The direct sequencing of SRY showed a new nonsense mutation in a codon of SRY gene flanking the 3" end of the HMG domain: a thymine is replaced by a guanine at position +387 in codon 129, resulting in the replacement of the amino acid tyrosine (TAT) by a stop codon (TAG).	Triethylenemelamine	245-248	sex determining region Y	Homo sapiens	74-77
2392122-1	1990	We have used two-dimensional gel electrophoresis (2DE) coupled with computer-assisted data analysis to analyze liver-protein expression in mice known to be heterozygous carriers of recessive lethal mutations induced in In(1)1Rk or In(7)13Rk inversion stocks by exposure to either triethylene melamine or ionizing radiation.	Triethylenemelamine	280-300	inversion, Chr 7, Roderick 13, distal	Mus musculus	231-240
33236626-4	2020	Herein, a cell-penetrating peptide TAT-KR-12 was derived from the trans-activating transcription (TAT) peptide and KR-12 (residues 18-29 of human cathelicidin LL-37).	Triethylenemelamine	35-38	cathelicidin antimicrobial peptide	Homo sapiens	159-164
34699930-11	2022	However only treatment with TAT resulted in regulatory CD4 T-cell drop and transient increased production of IL-2, CCL-5 and IFNgamma within the tumor.	Triethylenemelamine	28-31	CD4 molecule	Homo sapiens	55-58
34699930-11	2022	However only treatment with TAT resulted in regulatory CD4 T-cell drop and transient increased production of IL-2, CCL-5 and IFNgamma within the tumor.	Triethylenemelamine	28-31	interleukin 2	Homo sapiens	109-113
34699930-11	2022	However only treatment with TAT resulted in regulatory CD4 T-cell drop and transient increased production of IL-2, CCL-5 and IFNgamma within the tumor.	Triethylenemelamine	28-31	C-C motif chemokine ligand 5	Homo sapiens	115-120
34699930-11	2022	However only treatment with TAT resulted in regulatory CD4 T-cell drop and transient increased production of IL-2, CCL-5 and IFNgamma within the tumor.	Triethylenemelamine	28-31	interferon gamma	Homo sapiens	125-133
7870102-1	1995	The mutagenicity of the trifunctional alkylating (or cross-linking) agent TEM (triethylenemelamine or 2,4,6-tris(1-aziridinyl)-1,3,5-triazine) in the adenine-3 (ad-3) region was studied with a two-component heterokaryon (H-12) of Neurospora crassa.	Triethylenemelamine	79-98	tenomodulin	Mus musculus	74-77
7870102-1	1995	The mutagenicity of the trifunctional alkylating (or cross-linking) agent TEM (triethylenemelamine or 2,4,6-tris(1-aziridinyl)-1,3,5-triazine) in the adenine-3 (ad-3) region was studied with a two-component heterokaryon (H-12) of Neurospora crassa.	Triethylenemelamine	102-141	tenomodulin	Mus musculus	74-77
1582174-2	1992	A heterozygous mouse mutant exhibiting approximately 50% of wild-type glucose-6-phosphate isomerase (GPI) activity in blood was recovered in mutagenicity experiments after combined treatment of spermatogonia with triethylenemelamine and irradiation.	Triethylenemelamine	213-232	glucose-6-phosphate isomerase 1	Mus musculus	70-99
1582174-2	1992	A heterozygous mouse mutant exhibiting approximately 50% of wild-type glucose-6-phosphate isomerase (GPI) activity in blood was recovered in mutagenicity experiments after combined treatment of spermatogonia with triethylenemelamine and irradiation.	Triethylenemelamine	213-232	glucose-6-phosphate isomerase 1	Mus musculus	101-104
33809167-5	2021	We developed a TAT approach in a human melanoma xenograft model that stably expresses PD-L1 using a 213Bi-anti-human-PD-L1 mAb.	Triethylenemelamine	15-18	CD274 molecule	Homo sapiens	86-91
33809167-9	2021	This study demonstrates that anti-PD-L1 antibodies may be used efficiently for TAT treatment in melanoma.	Triethylenemelamine	79-82	CD274 molecule	Homo sapiens	34-39
34519946-11	2021	The protein and mRNA expression levels of TGF-beta1 and CTGF were significantly upregulated both in Tat-treated mouse myocardium and neonatal mouse cardiac fibroblasts.	Triethylenemelamine	100-103	transforming growth factor, beta 1	Mus musculus	42-51
34519946-11	2021	The protein and mRNA expression levels of TGF-beta1 and CTGF were significantly upregulated both in Tat-treated mouse myocardium and neonatal mouse cardiac fibroblasts.	Triethylenemelamine	100-103	cellular communication network factor 2	Mus musculus	56-60
34741242-1	2021	Previously we showed that Beclin1 has a regulatory role in the secretion of inflammatory molecules in glia after exposure to morphine and Tat (an HIV protein).	Triethylenemelamine	138-141	beclin 1, autophagy related	Mus musculus	26-33
34741242-7	2021	Interestingly, co-exposure to morphine and Tat increased sensitivity to pain in Becn1+/+ mice, but not in similarly treated Becn1+/- mice.	Triethylenemelamine	43-46	beclin 1, autophagy related	Mus musculus	80-85
34741242-8	2021	Brain homogenates from Becn1+/+ mice exposed to Tat, alone and in combination with morphine, showed increased secretion of pro-inflammatory cytokines and reduced expression of growth factors when compared to similarly treated Becn1+/- mice.	Triethylenemelamine	48-51	beclin 1, autophagy related	Mus musculus	23-28
34741242-9	2021	Likewise, increased neuronal loss was detected when both Tat and morphine were administered to Becn1+/+ mice, but not in similarly treated Becn1+/- mice.	Triethylenemelamine	57-60	beclin 1, autophagy related	Mus musculus	95-100
34741242-10	2021	Overall, our findings show that there is a Beclin1-driven interaction between Tat and morphine in glia and neurons.	Triethylenemelamine	78-81	beclin 1, autophagy related	Mus musculus	43-50
34741242-11	2021	Moreover, reduced glial-Beclin1 may provide a layer of protection to neurons under stressful conditions, such as when exposed to morphine and Tat.	Triethylenemelamine	142-145	beclin 1, autophagy related	Mus musculus	24-31
34519946-12	2021	However, co-administration of TGF-beta inhibitor abrogated the enhanced expression of collagen I induced by Tat in neonatal mouse cardiac fibroblasts.	Triethylenemelamine	108-111	transforming growth factor alpha	Mus musculus	30-38
34519946-13	2021	In conclusion, Tat contributes to HIV-related cardiac fibrosis through enhanced TGF-beta1-CTGF signaling cascade.	Triethylenemelamine	15-18	transforming growth factor beta 1	Homo sapiens	80-89
34519946-13	2021	In conclusion, Tat contributes to HIV-related cardiac fibrosis through enhanced TGF-beta1-CTGF signaling cascade.	Triethylenemelamine	15-18	cellular communication network factor 2	Homo sapiens	90-94
34445881-0	2021	Restoration of KCC2 Membrane Localization in Striatal Dopamine D2 Receptor-Expressing Medium Spiny Neurons Rescues Locomotor Deficits in HIV Tat-Transgenic Mice.	Triethylenemelamine	141-144	solute carrier family 12, member 5	Mus musculus	15-19
34527676-6	2021	These findings imply a novel molecular mechanism underlying HIV Tat-mediated increase of monocyte transmigration across the BBB, while also implicating a novel role of CXCR3-dependent monocyte transmigration in HIV Tat-mediated neuroinflammation.	Triethylenemelamine	215-218	C-X-C motif chemokine receptor 3	Homo sapiens	168-173
34182508-8	2021	The clinical success of decompression (p=0.0072), oral intake (p<0.0001) and change in serum albumin (p<0.0001) from decompression to surgery were significantly better in the SEMS compares to the TAT group.	Triethylenemelamine	196-199	albumin	Homo sapiens	87-100
34445881-10	2021	Dopamine D2 receptor-expressing medium spiny neurons (MSNs) were selectively vulnerable to Tat-induced KCC2 loss, with no changes observed in dopamine D1 receptor-expressing MSNs.	Triethylenemelamine	91-94	dopamine receptor D2	Mus musculus	0-20
34445881-10	2021	Dopamine D2 receptor-expressing medium spiny neurons (MSNs) were selectively vulnerable to Tat-induced KCC2 loss, with no changes observed in dopamine D1 receptor-expressing MSNs.	Triethylenemelamine	91-94	solute carrier family 12, member 5	Mus musculus	103-107
35301411-9	2022	BDNF-CT exerted cognitive-enhancing effects by reducing Tat-induced learning and memory deficits.	Triethylenemelamine	56-59	brain derived neurotrophic factor	Mus musculus	0-4
35269478-8	2022	GABAergic activity was significantly altered upon Tat exposure based on sex, whereas the effectiveness of PF3845 to suppress GABAergic activity in Tat transgenic mice was not altered by Tat or sex and involved CB1R-related mechanisms that depended on calcium signaling.	Triethylenemelamine	147-150	cannabinoid receptor 1 (brain)	Mus musculus	210-214
35269478-11	2022	Results highlight sex- and/or Tat-dependent alterations of GABAergic activity and eCB signaling in the prefrontal cortex of Tat transgenic mice and further increase our understanding about the role of FAAH inhibition in neuroHIV.	Triethylenemelamine	30-33	fatty acid amide hydrolase	Mus musculus	201-205
35269478-11	2022	Results highlight sex- and/or Tat-dependent alterations of GABAergic activity and eCB signaling in the prefrontal cortex of Tat transgenic mice and further increase our understanding about the role of FAAH inhibition in neuroHIV.	Triethylenemelamine	124-127	fatty acid amide hydrolase	Mus musculus	201-205
2613337-5	1989	Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime.	Triethylenemelamine	164-167	adhesion G protein-coupled receptor A2	Homo sapiens	208-213
35121786-8	2022	Notably, the magnitude of the associations between PCF/TAT and NAFLD/AO varied by the level of systemic inflammatory marker (hs-CRP level).	Triethylenemelamine	55-58	C-reactive protein	Homo sapiens	128-131
7121501-0	1982	Detection of triethylenemelamine-induced translocation heterozygotes in CD-1 mice: fertility and cytological methods.	Triethylenemelamine	13-32	CD1 antigen complex	Mus musculus	72-76
3941902-1	1986	A semisterile male translocation heterozygote [t(2; 14) 1Gso] that exhibited neurological symptoms and an inability to swim (diver) was found among the offspring of male mice treated with triethylenemelamine.	Triethylenemelamine	188-207	reciprocal translocation, Chr 2 and 14, Generoso 1	Mus musculus	47-60
33008928-22	2021	Conclusion: Our first clinical data for TAT using 225Ac-PSMA-I&T showed promising antitumor effect in advanced mCRPC even after failure of prior 177Lu-PSMA treatment with tolerable side effects.	Triethylenemelamine	40-43	folate hydrolase 1	Homo sapiens	56-60
33008928-22	2021	Conclusion: Our first clinical data for TAT using 225Ac-PSMA-I&T showed promising antitumor effect in advanced mCRPC even after failure of prior 177Lu-PSMA treatment with tolerable side effects.	Triethylenemelamine	40-43	folate hydrolase 1	Homo sapiens	151-155
33827943-5	2021	USP21 deubiquitylates Tat via its deubiquitinase activity, but a stronger ability to reduce Tat expression compared to Ub-KO showed that other mechanisms may contribute to USP21-mediated inhibition of Tat.	Triethylenemelamine	22-25	ubiquitin specific peptidase 21	Homo sapiens	0-5
33946474-4	2021	We hypothesized that HPA and/or HPG dysregulation contributes to Tat-mediated interactions with oxycodone, an opioid often prescribed to HIV patients, in females.	Triethylenemelamine	65-68	gonadotropin releasing hormone 1	Mus musculus	32-35
33862209-8	2021	CONCLUSIONS: The exogenous reinfection of drug-resistant strains played a vital role in the development of DR of Mtb isolates during TAT for DST, highlighting the need for both rapid DST methods and improved infection control.	Triethylenemelamine	133-136	metallothionein 1J, pseudogene	Homo sapiens	113-116
33827943-13	2021	First, USP21 deubiquitinates polyubiquitinated Tat causing Tat instability, and second USP21 reduces the mRNA levels of cyclin T1 (CycT1), an important component of P-TEFb, that leads 56 to Tat downregulation.	Triethylenemelamine	47-50	ubiquitin specific peptidase 21	Homo sapiens	7-12
33827943-13	2021	First, USP21 deubiquitinates polyubiquitinated Tat causing Tat instability, and second USP21 reduces the mRNA levels of cyclin T1 (CycT1), an important component of P-TEFb, that leads 56 to Tat downregulation.	Triethylenemelamine	47-50	cyclin T1	Homo sapiens	120-129
33827943-13	2021	First, USP21 deubiquitinates polyubiquitinated Tat causing Tat instability, and second USP21 reduces the mRNA levels of cyclin T1 (CycT1), an important component of P-TEFb, that leads 56 to Tat downregulation.	Triethylenemelamine	47-50	cyclin T1	Homo sapiens	131-136
33860213-2	2021	The TAT conjugate is comprised of the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate), conjugated to melanocortin receptor 1 specific peptidic ligand (MC1RL) using a linker moiety and chelation of the 225Ac radiometal.	Triethylenemelamine	4-7	melanocortin 1 receptor	Homo sapiens	122-145
33537927-2	2021	This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport.	Triethylenemelamine	95-98	solute carrier family 6 member 3	Homo sapiens	54-74
33537927-2	2021	This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport.	Triethylenemelamine	95-98	solute carrier family 6 member 3	Homo sapiens	76-80
33537927-9	2021	HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction.	Triethylenemelamine	6-9	solute carrier family 6 member 3	Homo sapiens	49-69
33537927-9	2021	HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction.	Triethylenemelamine	6-9	solute carrier family 6 member 3	Homo sapiens	71-75
33353867-16	2021	CONCLUSIONS: TAT with 225Ac-PSMA resulted in remarkable survival and biochemical responses in advanced mCRPC patients.	Triethylenemelamine	13-16	folate hydrolase 1	Homo sapiens	28-32
33613977-7	2021	The protein levels of GLUT1 and GLUT3 was downregulated in patients with Tat- and METH-induced BBB damage.	Triethylenemelamine	73-76	solute carrier family 2 member 1	Homo sapiens	22-27
33613977-7	2021	The protein levels of GLUT1 and GLUT3 was downregulated in patients with Tat- and METH-induced BBB damage.	Triethylenemelamine	73-76	solute carrier family 2 member 3	Homo sapiens	32-37
33122041-13	2021	CONCLUSION: The two rapid ESBL tests showed good performance and allowed the reduction of the TAT of the screening protocol for identification of ESBL carriers.	Triethylenemelamine	94-97	EsbL	Escherichia coli	26-30
33122041-13	2021	CONCLUSION: The two rapid ESBL tests showed good performance and allowed the reduction of the TAT of the screening protocol for identification of ESBL carriers.	Triethylenemelamine	94-97	EsbL	Escherichia coli	146-150
33327462-5	2020	The localization of the delivered Tat-p27 protein was also confirmted in the HT22 cells and hippocampus in gerbils.	Triethylenemelamine	34-37	cyclin-dependent kinase inhibitor 1B	Mus musculus	38-41
32870550-3	2020	To that end, we have designed and synthesized two naphthoquinone-dopamine-based hybrid small molecules, NQDA and Cl-NQDA, and demonstrated their ability to inhibit in vitro amyloid formation by alpha-Syn using ThT assay, CD, TEM, and Congo red birefringence.	Triethylenemelamine	225-228	synuclein alpha	Homo sapiens	194-203
32344154-7	2020	Using an inducible, Tat-transgenic mouse neuroHIV model, we found that chronic exposure to Tat also reduces KCC2.	Triethylenemelamine	20-23	solute carrier family 12, member 5	Mus musculus	108-112
32648573-6	2020	We used two kinds of anti-mesothelin antibodies, ET210-6 and ET210-28, to construct TAT drugs.	Triethylenemelamine	84-87	mesothelin	Homo sapiens	26-36
32461322-8	2020	Determining the mechanistic basis underlying the interaction between Tat and DAT/NET may reveal novel therapeutic possibilities for preventing the increase in comorbid conditions as well as HAND.	Triethylenemelamine	69-72	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	77-80
33208151-11	2020	CONCLUSION: Overall results demonstrate that 3 months of Tat exposure increased morphine tolerance and potentially innate immune tolerance evidenced by reductions in specific cytokines (e.g., IL-1alpha, IL-12p40) and microglial reactivity.	Triethylenemelamine	57-60	interleukin 1 alpha	Homo sapiens	192-201
32961826-11	2020	Our results demonstrate that TAT-mediated intracellular delivery of FADD protein can potentially recite apoptosis signaling with simultaneous regulation of anti-apoptotic and proinflammatory NF-kappaB signaling activation in cancer cells.	Triethylenemelamine	29-32	nuclear factor kappa B subunit 1	Homo sapiens	191-200
32344154-7	2020	Using an inducible, Tat-transgenic mouse neuroHIV model, we found that chronic exposure to Tat also reduces KCC2.	Triethylenemelamine	91-94	solute carrier family 12, member 5	Mus musculus	108-112
32453744-5	2020	In addition, we find increased expression of beta-site cleaving enzyme (BACE1), APP, and Abeta in human primary astrocytes (HPAs) exposed to Tat.	Triethylenemelamine	141-144	beta-secretase 1	Homo sapiens	72-77
32453744-5	2020	In addition, we find increased expression of beta-site cleaving enzyme (BACE1), APP, and Abeta in human primary astrocytes (HPAs) exposed to Tat.	Triethylenemelamine	141-144	amyloid beta precursor protein	Homo sapiens	89-94
32453744-8	2020	This is the first report implicating the role of the HIF-1alpha/lncRNABACE1-AS/BACE1 axis in Tat-mediated induction of astrocytic amyloidosis, which could be targeted as adjunctive therapies for HAND-associated Alzheimer-like comorbidity.	Triethylenemelamine	93-96	hypoxia inducible factor 1 subunit alpha	Homo sapiens	53-63
32453744-8	2020	This is the first report implicating the role of the HIF-1alpha/lncRNABACE1-AS/BACE1 axis in Tat-mediated induction of astrocytic amyloidosis, which could be targeted as adjunctive therapies for HAND-associated Alzheimer-like comorbidity.	Triethylenemelamine	93-96	beta-secretase 1	Homo sapiens	70-75
30305110-11	2018	Unexpectedly, when CCR5 was lost from glia, morphine appeared to entirely protect neurons from Tat-induced toxicity.	Triethylenemelamine	95-98	C-C motif chemokine receptor 5	Homo sapiens	19-23
32283831-12	2020	In spite of the antagonizing effects of Tat, a few genes identified in relevant gene networks remained downregulated, such as sirtuin 1, and the amyloid precursor protein (APP).	Triethylenemelamine	40-43	sirtuin 1	Homo sapiens	126-135
32283831-12	2020	In spite of the antagonizing effects of Tat, a few genes identified in relevant gene networks remained downregulated, such as sirtuin 1, and the amyloid precursor protein (APP).	Triethylenemelamine	40-43	amyloid beta precursor protein	Homo sapiens	145-170
31616141-13	2019	The potential of TAT-Tf-liposomes as efficient brain-targeted gene carriers in vitro and in vivo was suggested to be related to the presence of selected moieties on the nanoparticle surface.	Triethylenemelamine	17-20	inositol 1,4,5-triphosphate receptor 3	Mus musculus	21-23
30986866-11	2019	RESULTS:  Reduced MASP-1 plasma concentration was associated with DIC score >=5 (p = 0.02), impaired thrombin generation (p = 0.03) and lower plasma TAT complex levels (p = 0.03).	Triethylenemelamine	149-152	MBL associated serine protease 1	Homo sapiens	18-24
29349578-5	2018	Tat has been used as brain-penetrant carrier also in therapies for Alzheimer disease (AD), the most common form of dementia characterized by extracellular cerebral deposits of amyloid made up of Abeta peptide.	Triethylenemelamine	0-3	amyloid beta precursor protein	Homo sapiens	195-200
29349578-8	2018	Our results showed that Tat peptide binds amyloid deposits made up of Abeta, PrP, and immunoglobulin lambda chains in the brain and other tissues processed by alcoholic fixatives but not in formalin-fixed tissue.	Triethylenemelamine	24-27	amyloid beta precursor protein	Homo sapiens	70-75
29349578-8	2018	Our results showed that Tat peptide binds amyloid deposits made up of Abeta, PrP, and immunoglobulin lambda chains in the brain and other tissues processed by alcoholic fixatives but not in formalin-fixed tissue.	Triethylenemelamine	24-27	prion protein	Homo sapiens	77-80
26276395-6	2015	An inhibitory effect of Tat-conjugated peptides against IGF-1-stimulated phosphorylation of IGF-1 receptors was observed.	Triethylenemelamine	24-27	insulin like growth factor 1	Homo sapiens	56-61
28866799-0	2018	Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson"s Disease.	Triethylenemelamine	29-32	glial cell line derived neurotrophic factor	Mus musculus	71-75
27659560-9	2016	Furthermore, co-immunoprecipitation experiments revealed a potential physical interaction between Tat and ATX.	Triethylenemelamine	98-101	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	106-109
26276395-6	2015	An inhibitory effect of Tat-conjugated peptides against IGF-1-stimulated phosphorylation of IGF-1 receptors was observed.	Triethylenemelamine	24-27	insulin like growth factor 1	Homo sapiens	92-97
24666322-5	2014	Tat-induced potentiation of NMDA-evoked increases in [Ca(2+)]i peaked by 8 h and then adapted by gradually reversing to baseline by 24 h and eventually dropping below control by 48 h. Tat-induced potentiation of NMDA-evoked responses was blocked by inhibition of lipoprotein receptor-related protein (LRP) or Src tyrosine kinase.	Triethylenemelamine	0-3	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	309-312
25156524-3	2015	Tat caused a biphasic change in NMDAR function; NMDA-evoked increases in intracellular Ca(2+) were initially potentiated following 16 h exposure to Tat and then adapted by gradually returning to baseline by 24 h. Following Tat-induced NMDAR potentiation, a RhoA/Rho-associated protein kinase (ROCK) signaling pathway was activated; a subsequent remodeling of the actin cytoskeleton reduced NMDA-evoked increases in intracellular Ca(2+) .	Triethylenemelamine	0-3	ras homolog family member A	Homo sapiens	257-261
24666322-15	2014	Subsequently, Tat-induced NMDAR potentiation adapted by activation of a NOS/sGC/PKG pathway that attenuated NMDA-evoked increases in [Ca(2+)]i .	Triethylenemelamine	14-17	protein kinase cGMP-dependent 1	Homo sapiens	80-83
24666322-5	2014	Tat-induced potentiation of NMDA-evoked increases in [Ca(2+)]i peaked by 8 h and then adapted by gradually reversing to baseline by 24 h and eventually dropping below control by 48 h. Tat-induced potentiation of NMDA-evoked responses was blocked by inhibition of lipoprotein receptor-related protein (LRP) or Src tyrosine kinase.	Triethylenemelamine	0-3	LDL receptor related protein 1	Homo sapiens	263-299
24666322-5	2014	Tat-induced potentiation of NMDA-evoked increases in [Ca(2+)]i peaked by 8 h and then adapted by gradually reversing to baseline by 24 h and eventually dropping below control by 48 h. Tat-induced potentiation of NMDA-evoked responses was blocked by inhibition of lipoprotein receptor-related protein (LRP) or Src tyrosine kinase.	Triethylenemelamine	0-3	LDL receptor related protein 1	Homo sapiens	301-304
22534545-5	2012	Operation time was significantly longer in the TEM group than in the TAE group.During the median follow-up of 40 months, the LRR in the TEM group was lower than that in the TAE group,especially for tumors that are larger (&gt;3cm) and located higher (&gt;8cm from the anal verge) and pT1 carcinomas.	Triethylenemelamine	47-50	zinc finger protein 77	Homo sapiens	284-287
23190742-13	2012	In addition, LRRK2i decreased brain-specific angiogenesis inhibitor 1 (BAI1) receptor expression on BV-2 cells after Tat-treatment, a key receptor in phosphatidylserine-mediated phagocytosis.	Triethylenemelamine	117-120	adhesion G protein-coupled receptor B1	Mus musculus	30-69
23190742-13	2012	In addition, LRRK2i decreased brain-specific angiogenesis inhibitor 1 (BAI1) receptor expression on BV-2 cells after Tat-treatment, a key receptor in phosphatidylserine-mediated phagocytosis.	Triethylenemelamine	117-120	adhesion G protein-coupled receptor B1	Mus musculus	71-75
19220926-1	2009	A triosephosphate isomerase (TPI) mutant, Tpi1(a-m6Neu), with approximately 57% residual enzyme activity in blood compared with wild-type was detected among offspring of triethylenemelamine-treated male mice.	Triethylenemelamine	170-189	triosephosphate isomerase 1	Mus musculus	2-27
19107119-4	2009	In TF-1 and mouse embryonic stem cells, the uptake of a novel detachable TAT-conjugated glycogen synthase kinase-3 (GSK-3) peptide inhibitor was enhanced by an order of magnitude without affecting the cell viability.	Triethylenemelamine	73-76	glycogen synthase kinase 3 beta	Mus musculus	88-114
19107119-4	2009	In TF-1 and mouse embryonic stem cells, the uptake of a novel detachable TAT-conjugated glycogen synthase kinase-3 (GSK-3) peptide inhibitor was enhanced by an order of magnitude without affecting the cell viability.	Triethylenemelamine	73-76	glycogen synthase kinase 3 beta	Mus musculus	116-121
19220926-1	2009	A triosephosphate isomerase (TPI) mutant, Tpi1(a-m6Neu), with approximately 57% residual enzyme activity in blood compared with wild-type was detected among offspring of triethylenemelamine-treated male mice.	Triethylenemelamine	170-189	triosephosphate isomerase 1	Mus musculus	29-32
19220926-1	2009	A triosephosphate isomerase (TPI) mutant, Tpi1(a-m6Neu), with approximately 57% residual enzyme activity in blood compared with wild-type was detected among offspring of triethylenemelamine-treated male mice.	Triethylenemelamine	170-189	triosephosphate isomerase 1	Mus musculus	42-54